Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency Anemia

Completed

Conditions studied: Iron Deficiency Anemia (IDA)

In brief

The primary objective of this study is to compare the total costs to sites and payers of administering IV iron over the 30-day observation period for subjects with IDA who receive Ferric Carboxymaltose (FCM) relative to those who receive iron sucrose, iron dextran, and ferumoxytol.

Key facts

Study ID

NCT01984554

Run by

American Regent, Inc.

People needed

551

Starts

2013-09-01

Expected to finish

2014-12-01

Last updated by the study team

2018-01-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must present for the first dose of a current cycle of IV treatment for IDA
• Must be over 18 years of age
• Must be willing and able to provide informed consent, including permission to obtain information from their medical records.
• Must be able to read and understand English.

You may not qualify if…

• Subjects not diagnosed with IDA.
• Subjects requiring more than one treatment cycle within 30 days.
• Subjects receiving maintenance IV iron therapy.
• Subjects treated with IV iron within the 30-day period prior to study enrollment.
• Subjects who received investigational medication in the six months prior to the study.

Where it is running

• Luitpold Pharmaceuticals, Inc. — Norristown, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.